Hundreds of millions of people worldwide, chronically suffer from Hepatitis each year. With a person dying every 30 seconds from a hepatitis related illness – even in the current COVID-19 pandemic – one cannot neglect its severity.1 The major challenge we face in eradicating this disease today is to preventing the fatality of chronic infection and avoiding acute infection in at-risk populations.2
The burning topic of discussion of today’s vaccine roll out is ‘How much is the efficacy of the vaccine?’ But is this the real sphere of concern?
COVAXIN™ (BBV152) showed long-term antibody and T-cell memory responses (3-months after vaccination) in phase 1 volunteers, and tolerable safety outcomes with enhanced humoral & cell-mediated immune responses in the Phase 2 study.
COVAXIN™ (BBV152) demonstrated acceptable safety profile and high immune response, which induced T-cell responses in Phase 1 study.
COVAXIN™ (BBV152) Shows Demonstration of Protective Efficacy and Immunogenicity in Non-Human Primates
Vaccines are biological products that protect people against many diseases that can be very dangerous and fatal, by producing immunity to a specific disease. They reduce risks of getting a disease by working with body’s natural defenses to build protection. Till date, several vaccines